Americas · Regional markets · Financial Post

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Published by Financial Post · Canada 3 h ago

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional…

Read the full article on Financial Post Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (financialpost.com)

Also worth reading

BNN Bloomberg

Beyond big tech: 6 quality dividend stocks to own: Jon Erlichman

El Cronista

Fin de semana con lluvias en Buenos Aires: qué días habrá chaparrones y cuánto bajará la temperatura

Diario Financiero

Richard Lapper: “Hay un empate técnico… la elección podría ir a cualquiera de los dos lados”.

La República

Citigroup reúne a analistas en México de cara a salida a bolsa de Banamex

Gestión

Gerson Añaños de Grupo AJE: “Nuestro desafío es crecer sin perder agilidad”

Bloomberg Línea